PTO/SB/30 (01-08)

Approved for use through 03/31/2008. OMB 0651-0031 Under the Penerwork Reduction Act of 1995, no n

Request Request	ited to respond to a collection of information unless it contains a valid OMB control number		
for Continued Examination (RCE) Transmittal  Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Application Number	10/927,857	
	Filing Date	August 27, 2004	
	First Named Inventor	Andrew Acheampong	
	Art Unit	1654	
	Examiner Name	Marcela M. Cordero Garcia	
	Attorney Docket Number	17618/AP)	

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Docket No. 17618(AP) Serial No. 10/927,857

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Acheampong et al Examiner: Marcela M. Cordero Garcia

Serial No.: 10/927,857 | Group Art Unit: 1654

Filed: August 27, 2004 Confirmation No.: 2409

For: METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS

Customer No.: 051957

### Response

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The Applicants request continued examination of the above-referenced application, thereby withdrawing their pending appeal. They submit with this paper a list of amended claims at page 2. Remarks follow at page 3.



### **CLAIMS**

The following listing of claims will replace all previous versions of claims presented in this application:

- 1. 40 (Canceled).
- 41. (New) A composition for treating an eye of a human or animal comprising cyclosporin A, castor oil, Pemulen, glycerin, and water, wherein the cyclosporin A is in an amount less than 0.05% by weight; the Pemulin is in amount equal to or greater than 1.0% by weight; the glycerin is in amount equal to or less than 1.0% by weight; and wherein the ratio of cyclosporin A to castor oil is less than 0.04.



### **REMARKS**

The applicants have reviewed the prosecution history of the present application and co-pending application no. 11/897,177, and have found significant errors. The purpose of this request for continued examination is to bring those errors to the attention of the examiner, to file an IDS, and to submit new claims.

### The Ding reference and obviousness

The present application describes two compositions at Example 1. Composition II is as follows:

### **Present Application**

	Composition II	
Cyclosporin A	0.05 %	
Castor Oil	1.25 %	
Polysorbate 80	1.00 %	
Pemulin®	0.05 %	
Glycerine	2.20 %	
NaOH	qs	
Purified water	qs	
рН	7.2-7.6	
Ratio cyclosporin to castor oil	0.04	

Composition II fell within the scope of the claims that the applicants previously presented for prosecution.

In a final action dated July 2, 2007, the Office rejected the claims under 35 U.S.C. § 103 in view of U.S. Patent No. 5,474,979 (the "Ding reference). The Ding reference discloses at Examples 1B, 1D, and 1E the compositions shown on the following page.



### **Ding Reference**

	Example 1B	Example 1D	Example 1E
Cyclosporin A	0.40 %	0.05 %	0.05 %
Castor Oil	5.00 %	0.625 %	0.625 %
Polysorbate 80	1.00 %	1.00 %	1.00 %
Pemulin®	0.05 %	0.05 %	0.05 %
Glycerine	2.20 %	2.20 %	2.20 %
NaOH	qs	qs	qs
Purified water	qs	qs	qs
рН	7.2-7.6	7.2-7.6	7.2-7.6
Ratio cyclosporin to castor oil	0.08	0.08	0.08

The only difference between Composition II of the present application, and Examples 1D and 1E of the Ding reference, is that Example 1D has more cyclosporin, and Example 1E has less castor oil. The only difference between Composition II and Example 1B, is that Example 1B has less cyclosporin and less castor oil, although both compositions have cyclosporin and castor oil in the same proportion. Stated differently, Composition II has the same amount of cyclosporin as Example 1E, the same amount of castor oil as Example 1D, and the same proportion of cyclosporin to castor oil as Example 1B. As shown on the following page, the compositions are otherwise the same.



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

